Fulcrum Therapeutics, Inc

(NASDAQ:FULC)

Latest On Fulcrum Therapeutics, Inc (FULC):

Date/Time Type Description Signal Details
2023-05-24 17:06 ESTNewsFulcrum Therapeutics: FSHD Steadily Advancing In Phase 3, Optionality With SCDN/A
2023-05-16 00:01 ESTNewsFulcrum Therapeutics, Inc. (FULC) Q1 2023 Earnings Call TranscriptN/A
2023-05-15 10:14 ESTNewsFulcrum Therapeutics GAAP EPS of -$0.41 beats by $0.05, revenue of $0.3M misses by $0.68MN/A
2023-05-15 10:14 ESTNewsFulcrum Therapeutics appoints new executive chiefN/A
2023-05-05 01:13 ESTNewsFulcrum slips as Goldman Sachs downgrades on limited catalyst pathN/A
2023-04-25 17:38 ESTNewsFulcrum Therapeutics: Barrage Of Bad News In 2023 But Key Catalysts RemainN/A
2023-04-05 22:41 ESTNewsFulcrum Therapeutics CFO resignsN/A
2023-03-10 23:32 ESTNewsFulcrum Therapeutics downgraded to neutral at Credit Suisse on sickle cell candidateN/A
2023-03-10 23:31 ESTNewsFulcrum Therapeutics, Inc. (FULC) Q4 2022 Earnings Call TranscriptN/A
2023-03-09 16:52 ESTNewsFulcrum Therapeutics GAAP EPS of -$0.50 misses by $0.01, revenue of $0.7M misses by $1.19MN/A
2023-03-09 16:52 ESTNewsFulcrum plunges 23% after Q4 update as medical chief departsN/A
2023-02-24 17:52 ESTNewsFulcrum Therapeutics plunges 55% on clinical hold for sickle cell treatmentsN/A
2023-02-13 20:23 ESTNewsFulcrum's Losmapimod: A Potential Aid, But Its Ability To Modify The Disease Remains UncertainN/A
2023-01-18 07:27 ESTNewsFulcrum Therapeutics shares slide after pricing $125M upsized stock offeringN/A
2023-01-17 20:15 ESTNewsFulcrum Therapeutics commences $100M underwritten public offering of sharesN/A
2023-01-04 19:34 ESTNewsFulcrum Therapeutics names new CEO and provides business outlookN/A
2022-11-12 22:51 ESTNewsFulcrum Therapeutics, Inc. (FULC) Q3 2022 Earnings Call TranscriptN/A
2022-11-08 12:30 ESTNewsFulcrum Therapeutics GAAP EPS of -$0.51 beats by $0.11, revenue of $1.18M misses by $1.36MN/A
2022-11-07 19:00 ESTNewsFulcrum Therapeutics names new chief medical officer, chief scientific officerN/A
2022-08-16 08:01 ESTNewsFulcrum Therapeutics stock dips on offering of $75M sharesN/A
2022-08-16 08:01 ESTNewsFulcrum prices ~$75M stock offeringN/A
2022-08-12 02:43 ESTNewsFulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-11 09:44 ESTNewsFulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06MN/A
2022-07-11 19:26 ESTNewsFulcrum Therapeutics says chief medical officer Christopher Morabito to leaveN/A
2022-07-06 05:55 ESTNewsFulcrum begins dosing in late-stage study of losmapimod for rare muscle disorderN/A
2022-06-28 04:00 ESTNewsFulcrum Therapeutics: Value Loss On SCD Data Update Is TellingN/A
2022-06-10 23:46 ESTNewsFulcrum crashes 48% after announcing early-stage data sickle cell disease candidateN/A
2022-06-08 03:53 ESTNewsFulcrum gains as Merck ends deal for lung disease candidatesN/A
2022-05-10 06:03 ESTNewsFulcrum Therapeutics' (FULC) CEO Bryan Stuart on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-09 10:26 ESTNewsFulcrum Therapeutics GAAP EPS of -$0.64 misses by $0.02, revenue of $2.6M misses by $1.34MN/A
2022-03-08 13:53 ESTNewsFulcrum rises as Oppenheimer highlights sickle cell disease candidateN/A
2022-03-03 11:48 ESTNewsFulcrum Therapeutics GAAP EPS of -$0.58 beats by $0.09, revenue of $5.06M beats by $1.54MN/A
2022-03-03 11:48 ESTNewsFulcrum plans phase 3 trial of losmapimod to treat rare muscle disorderN/A
2022-03-03 11:48 ESTNewsFulcrum Therapeutics, Inc.'s (FULC) CEO Bryan Stuart On Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-11 21:58 ESTNewsFulcrum Therapeutics grants inducement options to one new employeeN/A
2022-01-08 15:26 ESTNewsBiogen, Galapagos and Ultragenyx among key biotech calls at Morgan Stanley for 2022N/A
2022-01-04 13:05 ESTNewsFulcrum Therapeutics hires CFON/A
2021-11-06 20:44 ESTNewsFulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q3 2021 results - Earnings Call TranscriptN/A
2021-09-03 15:55 ESTNewsFulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry PointN/A
2021-08-12 17:25 ESTNewsFulcrum Therapeutics raises $125M via equity offeringN/A
2021-08-11 21:00 ESTNewsBluebird bio price target cut; Fulcrum upgraded as Morgan Stanley shakes up SCD coverageN/A
2021-08-11 01:17 ESTNewsFulcrum Therapeutics surges on early-stage results for sickle cell disease therapyN/A
2021-08-11 01:16 ESTNewsFulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-11 01:15 ESTNewsFulcrum Therapeutics more than doubles as Stifel raises price targetN/A
2021-08-11 01:15 ESTNewsFulcrum Therapeutics shares under pressure after $100M capital raiseN/A
2021-07-21 09:26 ESTNewsFulcrum Therapeutics reports results mid-stage losmapimod study in rare disabling diseaseN/A
2021-07-21 09:26 ESTNewsStifel nearly doubles Fulcrum price target, assumes 354% upsideN/A
2021-07-21 09:24 ESTNewsMRIN, ALT, FLXN and FULC among after-hours moversN/A
2021-05-06 12:07 ESTNewsFulcrum Therapeutics beats on revenueN/A
2021-05-06 12:06 ESTNewsFulcrum Therapeutics has a new medical chiefN/A

About Fulcrum Therapeutics, Inc (FULC):

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and ß-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

FULC Quotes by TradingView

See Advanced Chart

General

  • Name Fulcrum Therapeutics, Inc
  • Symbol FULC
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 73
  • Fiscal Year EndDecember
  • IPO Date2019-07-18
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Web URLhttp://www.fulcrumtx.com
View More

Valuation

  • Trailing PE 267
  • Price/Sales (Trailing 12 Mt.) 34.37
  • Price/Book (Most Recent Quarter) 4.11
  • Enterprise Value Revenue 31.49
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.87
  • Next Year EPS Estimate -$3.06
  • Next Quarter EPS Estimate -$0.66
  • Operating Margin -812%
  • Return on Assets -37%
  • Return on Equity -78%
  • Revenue 8.82 million
  • Earnings Per Share -$50.40
  • Revenue Per Share $0.35
  • Gross Profit -46839000
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 405.79 million
  • EBITDA -67074000
  • PE Ratio -26.37
  • Analyst Target Price $18
  • Book Value Per Share $4.53
View More

Share Statistics

  • Shares Outstanding 32.67 million
  • Shares Float 18.96 million
  • % Held by Insiders 3552%
  • % Held by Institutions 76.11%
  • Shares Short 690946
  • Shares Short Prior Month 724097
  • Short Ratio 4.81
  • Short % of Float 3%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • 52 Week High $22.39
  • 52 Week Low $7.01
  • 50 Day Moving Average 12.75
  • 200 Day Moving Average 11.21
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Fulcrum Therapeutics, Inc (FULC) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Fulcrum Therapeutics, Inc (FULC) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-04$4.23 million-$0.63-$0.7313.1%
2020-09-302020-11-10$N/A-$0.70-$0.64-9.8%
2020-06-302020-08-11$N/A-$0.66-$0.7511.61%
2020-03-312020-05-13$750000-$0.81-$0.76-6.58%
2019-12-312020-03-05$N/A-$0.71-$0.8819.62%
2019-09-302019-11-14$N/A-$0.97-$0.72-34.72%
2019-06-302019-08-26$N/A-$0.71-$0.755.33%

Fulcrum Therapeutics, Inc (FULC) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Fulcrum Therapeutics, Inc (FULC) Chart:

Fulcrum Therapeutics, Inc (FULC) News:

Below you will find a list of latest news for Fulcrum Therapeutics, Inc (FULC) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Fulcrum Therapeutics, Inc (FULC) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-07-1710CALL0 1813.1TRUE00
2026-07-1720CALL0 50TRUE00
2026-07-1730.64CALL0 362100.34TRUE00
2026-07-1740CALL0 36188.28FALSE00
2026-07-1750CALL0 0366.32FALSE00
2026-07-1760CALL0 0752.18FALSE00
2026-07-1770CALL0 0952.5FALSE00
2026-07-1780CALL0 10448.61FALSE00
2026-07-1790CALL0 01078.4FALSE00
2026-07-17100CALL0 11052.52FALSE00
2026-07-17110CALL0 01203.05FALSE00
2026-07-17120CALL0 01039.99FALSE00
2026-07-17130CALL0 01268.33FALSE00
2026-07-1710PUT0 20FALSE00
2026-07-1720PUT0 31211.62FALSE00
2026-07-1730PUT0 4511102.51FALSE00
2026-07-1740PUT0 310TRUE00
2026-07-1750PUT0 10TRUE00
2026-07-1760PUT0 00TRUE00
2026-07-1770PUT0 00TRUE00
2026-07-1780PUT0 00TRUE00
2026-07-1790PUT0 00TRUE00
2026-07-17100PUT0 00TRUE00
2026-07-17110PUT0 00TRUE00
2026-07-17120PUT0 00TRUE00
2026-07-17130PUT0 00TRUE00
2026-08-2110CALL0 0331.48TRUE00
2026-08-2120CALL0 0166.13TRUE00
2026-08-2130CALL0 3104.01TRUE00
2026-08-2140CALL0 6748.95FALSE00
2026-08-2150CALL0 10320.21FALSE00
2026-08-2160CALL0 0356.71FALSE00
2026-08-2170CALL0 1225.19FALSE00
2026-08-2110PUT0 00FALSE00
2026-08-2120.2PUT1 0348.12FALSE0.20
2026-08-2130.1PUT13 86558.42FALSE00
2026-08-2140PUT0 200TRUE00
2026-08-2150PUT0 00TRUE00
2026-08-2160PUT0 00TRUE00
2026-08-2170PUT0 00TRUE00
2026-09-1810CALL0 2254.12TRUE00
2026-09-1820CALL0 0153.01TRUE00
2026-09-1830CALL0 23108.75TRUE00
2026-09-1840CALL0 134356.27FALSE00
2026-09-1850CALL0 213180.06FALSE00
2026-09-1860CALL0 1195.9FALSE00
2026-09-1870CALL0 41217.7FALSE00
2026-09-1880CALL0 61235.42FALSE00
2026-09-1890CALL0 16288.3FALSE00
2026-09-18100CALL0 1263.11FALSE00
2026-09-18110CALL0 7274.33FALSE00
2026-09-18120CALL0 1284.3FALSE00
2026-09-18130CALL0 0293.26FALSE00
2026-09-18140CALL0 0301.39FALSE00
2026-09-18150CALL0 20308.82FALSE00
2026-09-18160CALL0 20363FALSE00
2026-09-18170CALL0 1321.98FALSE00
2026-09-18180CALL0 1327.87FALSE00
2026-09-18200CALL0 0333.96FALSE00
2026-09-1810PUT0 0535.67FALSE00
2026-09-1820PUT0 65276.42FALSE00
2026-09-1830PUT0 311767.87FALSE00
2026-09-1840PUT0 7127.42TRUE00
2026-09-1850PUT0 00TRUE00
2026-09-1860PUT0 00TRUE00
2026-09-1870PUT0 90TRUE00
2026-09-1880PUT0 50TRUE00
2026-09-1890PUT0 0222.73TRUE00
2026-09-18100PUT0 2245.3TRUE00
2026-09-18110PUT0 0257.09TRUE00
2026-09-18120PUT0 0267.64TRUE00
2026-09-18130PUT0 0277.2TRUE00
2026-09-18140PUT0 0276.39TRUE00
2026-09-18150PUT0 00TRUE00
2026-09-18160PUT0 00TRUE00
2026-09-18170PUT0 00TRUE00
2026-09-18180PUT0 00TRUE00
2026-09-18200PUT0 00TRUE00
2026-12-1810CALL0 3314.76TRUE00
2026-12-1820CALL0 172.07TRUE00
2026-12-1830CALL0 3171.59TRUE00
2026-12-1840.38CALL20 370663.54FALSE0.380
2026-12-1850CALL0 10292.62FALSE00
2026-12-1860CALL0 0160.38FALSE00
2026-12-1870CALL0 0172.22FALSE00
2026-12-1880CALL0 0178.63FALSE00
2026-12-1890CALL0 0185.85FALSE00
2026-12-18100CALL0 0194.4FALSE00
2026-12-18110CALL0 0204.63FALSE00
2026-12-18120CALL0 0208.54FALSE00
2026-12-18130CALL0 0214.52FALSE00
2026-12-18140CALL0 0219.95FALSE00
2026-12-18150CALL0 0224.9FALSE00
2026-12-18160CALL0 0229.46FALSE00
2026-12-1810PUT0 00FALSE00
2026-12-1820PUT0 174.04FALSE00
2026-12-1830PUT0 217191.93FALSE00
2026-12-1840PUT0 0138.47TRUE00
2026-12-1850PUT0 053.32TRUE00
2026-12-1860PUT0 0107.78TRUE00
2026-12-1870PUT0 00TRUE00
2026-12-1880PUT0 0128.89TRUE00
2026-12-1890PUT0 0139.37TRUE00
2026-12-18100PUT0 20TRUE00
2026-12-18110PUT0 00TRUE00
2026-12-18120PUT0 00TRUE00
2026-12-18130PUT0 00TRUE00
2026-12-18140PUT0 00TRUE00
2026-12-18150PUT0 0150.25TRUE00
2026-12-18160PUT0 0180.56TRUE00
2027-01-1510CALL0 3207.64TRUE00
2027-01-1520CALL0 30194.27TRUE00
2027-01-1530CALL0 30260.45TRUE00
2027-01-1540CALL0 8463.2FALSE00
2027-01-1550.27CALL0 54369.27FALSE00
2027-01-1560CALL0 0167.74FALSE00
2027-01-1570CALL0 86183.62FALSE00
2027-01-1580CALL0 0192.01FALSE00
2027-01-1590CALL0 2183.72FALSE00
2027-01-15100CALL0 473184.13FALSE00
2027-01-15110CALL0 0173.19FALSE00
2027-01-15120CALL0 21179.29FALSE00
2027-01-15150CALL0 3933234.93FALSE00
2027-01-15170CALL0 17243.09FALSE00
2027-01-15200CALL0 1253.34FALSE00
2027-01-15220CALL0 0233.94FALSE00
2027-01-15250CALL0 41259.35FALSE00
2027-01-15270CALL0 91271.39FALSE00
2027-01-1510PUT0 0104.95FALSE00
2027-01-1520PUT0 0220.51FALSE00
2027-01-1530PUT0 28171.16FALSE00
2027-01-1540PUT0 2131.19TRUE00
2027-01-1550PUT0 12374.68TRUE00
2027-01-1560PUT0 080.36TRUE00
2027-01-1570PUT0 1130.85TRUE00
2027-01-1580PUT0 093.66TRUE00
2027-01-1590PUT0 0102.91TRUE00
2027-01-15100PUT0 0132.82TRUE00
2027-01-15110PUT0 0126.49TRUE00
2027-01-15120PUT0 00TRUE00
2027-01-15150PUT0 00TRUE00
2027-01-15170PUT0 00TRUE00
2027-01-15200PUT0 00TRUE00
2027-01-15220PUT0 00TRUE00
2027-01-15250PUT0 00TRUE00
2027-01-15270PUT0 00TRUE00

Latest FULC Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST48$4.18
Jun 13, 2022 7:59 PM EST10$4.18
Jun 13, 2022 7:59 PM EST100$4.185
Jun 13, 2022 7:59 PM EST100$4.18
Jun 13, 2022 7:59 PM EST112$4.18

Fulcrum Therapeutics, Inc (FULC) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320018278/0000899243-20-018278-index.htm
2019-05-29UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1680581/000000000019009042/0000000000-19-009042-index.htm
2019-06-19UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1680581/000000000019009993/0000000000-19-009993-index.htm
2020-06-24UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1680581/000000000020005645/0000000000-20-005645-index.htm
2020-08-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1680581/000000000020007385/0000000000-20-007385-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1680581/000031506620000982/0000315066-20-000982-index.htm
2020-09-18SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1680581/000089914020000435/0000899140-20-000435-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924319019806/0000899243-19-019806-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924319019807/0000899243-19-019807-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924319019809/0000899243-19-019809-index.htm
2019-07-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924319020026/0000899243-19-020026-index.htm
2019-07-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924319020029/0000899243-19-020029-index.htm
2019-07-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924319020073/0000899243-19-020073-index.htm
2020-01-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320000461/0000899243-20-000461-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320000462/0000899243-20-000462-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320002034/0000899243-20-002034-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320002035/0000899243-20-002035-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320002037/0000899243-20-002037-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320002040/0000899243-20-002040-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320002041/0000899243-20-002041-index.htm
2020-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320003272/0000899243-20-003272-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320005299/0000899243-20-005299-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320005300/0000899243-20-005300-index.htm
2020-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320005958/0000899243-20-005958-index.htm
2020-03-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320006590/0000899243-20-006590-index.htm
2020-05-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320012820/0000899243-20-012820-index.htm
2020-05-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320012822/0000899243-20-012822-index.htm
2020-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320014415/0000899243-20-014415-index.htm
2020-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320014416/0000899243-20-014416-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320014552/0000899243-20-014552-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320014719/0000899243-20-014719-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320014721/0000899243-20-014721-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/0000899243-20-014722-index.htm
2020-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320015063/0000899243-20-015063-index.htm
2020-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/0000899243-20-015245-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320015437/0000899243-20-015437-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/0000899243-20-015623-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320015784/0000899243-20-015784-index.htm
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320015959/0000899243-20-015959-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320016382/0000899243-20-016382-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320016496/0000899243-20-016496-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320016497/0000899243-20-016497-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320016498/0000899243-20-016498-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320016499/0000899243-20-016499-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320016500/0000899243-20-016500-index.htm
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320017758/0000899243-20-017758-index.htm
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320017761/0000899243-20-017761-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320018121/0000899243-20-018121-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320018278/0000899243-20-018278-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320018815/0000899243-20-018815-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320018817/0000899243-20-018817-index.htm
2020-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320024982/0000899243-20-024982-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000090342319000302/0000903423-19-000302-index.htm
2019-05-01DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1680581/000091205719000198/0000912057-19-000198-index.htm
2019-06-06DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1680581/000091205719000241/0000912057-19-000241-index.htm
2020-02-20SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1680581/000091957420001785/0000919574-20-001785-index.htm
2019-06-21S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1680581/000104746919003793/0001047469-19-003793-index.htm
2019-07-08S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1680581/000104746919004014/0001047469-19-004014-index.htm
2019-07-12S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1680581/000104746919004158/0001047469-19-004158-index.htm
2019-07-18424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1680581/000104746919004265/0001047469-19-004265-index.htm
2019-07-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000104746919004324/0001047469-19-004324-index.htm
2019-06-21CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1680581/000110465919037024/0001104659-19-037024-index.htm
2019-06-26CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1680581/000110465919037583/0001104659-19-037583-index.htm
2019-07-128-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1680581/000110465919040208/0001104659-19-040208-index.htm
2019-07-15CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040331/0001104659-19-040331-index.htm
2019-07-15CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040333/0001104659-19-040333-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040809/0001104659-19-040809-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040810/0001104659-19-040810-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040811/0001104659-19-040811-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040812/0001104659-19-040812-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040813/0001104659-19-040813-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040814/0001104659-19-040814-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040815/0001104659-19-040815-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040816/0001104659-19-040816-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040817/0001104659-19-040817-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040818/0001104659-19-040818-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040819/0001104659-19-040819-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040820/0001104659-19-040820-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040821/0001104659-19-040821-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040965/0001104659-19-040965-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040966/0001104659-19-040966-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040967/0001104659-19-040967-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040968/0001104659-19-040968-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040969/0001104659-19-040969-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040970/0001104659-19-040970-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040971/0001104659-19-040971-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040972/0001104659-19-040972-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040973/0001104659-19-040973-index.htm
2019-07-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919041303/0001104659-19-041303-index.htm
2019-07-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919041304/0001104659-19-041304-index.htm
2019-07-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919041306/0001104659-19-041306-index.htm
2019-07-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919041307/0001104659-19-041307-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1680581/000110465920020454/0001104659-20-020454-index.htm
2019-07-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000114036119013355/0001140361-19-013355-index.htm
2019-07-29SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1680581/000114420419036332/0001144204-19-036332-index.htm
2019-07-29SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1680581/000119312519204925/0001193125-19-204925-index.htm
2019-08-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000119312519228512/0001193125-19-228512-index.htm
2019-08-26S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1680581/000119312519228520/0001193125-19-228520-index.htm
2019-10-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000119312519262065/0001193125-19-262065-index.htm
2019-12-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000119312519325397/0001193125-19-325397-index.htm
2020-01-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000119312520001768/0001193125-20-001768-index.htm
2020-02-05SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1680581/000119312520025424/0001193125-20-025424-index.htm
2020-02-05SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1680581/000119312520025429/0001193125-20-025429-index.htm
2020-03-05S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1680581/000119312520063092/0001193125-20-063092-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1680581/000119312520124813/0001193125-20-124813-index.htm
2020-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1680581/000119312520124825/0001193125-20-124825-index.htm
2020-06-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000119312520165696/0001193125-20-165696-index.htm
2020-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000119312520166654/0001193125-20-166654-index.htm
2020-06-22S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1680581/000119312520175588/0001193125-20-175588-index.htm
2020-06-24CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1680581/000119312520177487/0001193125-20-177487-index.htm
2020-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000119312520181057/0001193125-20-181057-index.htm
2020-07-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000119312520197820/0001193125-20-197820-index.htm
2020-08-11S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1680581/000119312520215668/0001193125-20-215668-index.htm
2020-08-11POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1680581/000119312520215674/0001193125-20-215674-index.htm
2020-08-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1680581/000119312520219029/0001193125-20-219029-index.htm
2019-07-15CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1680581/000135445719000348/0001354457-19-000348-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1680581/000138713120001784/0001387131-20-001784-index.htm
2019-06-05DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1680581/000141057819000287/0001410578-19-000287-index.htm
2019-08-2610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680581/000156459019032952/0001564590-19-032952-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000156459019043359/0001564590-19-043359-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680581/000156459019043378/0001564590-19-043378-index.htm
2020-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000156459020008800/0001564590-20-008800-index.htm
2020-03-0510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1680581/000156459020008951/0001564590-20-008951-index.htm
2020-04-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000156459020014860/0001564590-20-014860-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000156459020024846/0001564590-20-024846-index.htm
2020-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680581/000156459020024866/0001564590-20-024866-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000156459020039117/0001564590-20-039117-index.htm
2020-08-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680581/000156459020039121/0001564590-20-039121-index.htm
2016-07-25DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000168058116000001/0001680581-16-000001-index.htm
2017-05-10DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000168058117000001/0001680581-17-000001-index.htm
2017-07-25D/ANotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000168058117000002/0001680581-17-000002-index.htm
2018-09-05DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000168058118000002/0001680581-18-000002-index.htm
2020-06-11DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000168058120000001/0001680581-20-000001-index.htm
2019-07-17EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1680581/999999999519001628/9999999995-19-001628-index.htm
2020-06-26EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1680581/999999999520001702/9999999995-20-001702-index.htm
2020-08-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1680581/999999999520002111/9999999995-20-002111-index.htm
2020-08-17EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1680581/999999999520002175/9999999995-20-002175-index.htm
2019-05-13SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1680581/999999999719004388/9999999997-19-004388-index.htm
2019-06-20SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1680581/999999999719005683/9999999997-19-005683-index.htm

Fulcrum Therapeutics, Inc (FULC) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Fulcrum Therapeutics, Inc (FULC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 3552%
Institutional Ownership: 7611%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-02-19Owen B. WallaceChief Scientific OfficerSell6,088.0020.00121,760.00127,088.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320005299/0000899243-20-005299-index.htm
2020-05-26Owen B. WallaceChief Scientific OfficerSell412.0020.008,240.00127,088.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014416/0000899243-20-014416-index.htm
2020-05-27Owen B. WallaceChief Scientific OfficerSell448.0020.008,960.00127,088.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014552/0000899243-20-014552-index.htm
2020-05-28Owen B. WallaceChief Scientific OfficerSell2,232.0020.0044,640.00127,088.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014719/0000899243-20-014719-index.htm
2020-06-30Owen B. WallaceChief Scientific OfficerSell141.0020.002,820.00127,088.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320018121/0000899243-20-018121-index.htm
2020-07-08Owen B. WallaceChief Scientific OfficerSell2,951.0020.0059,020.00127,088.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320018817/0000899243-20-018817-index.htm
2020-06-30Owen B. WallaceChief Scientific OfficerBuy141.007.841,105.44127,229.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320018121/0000899243-20-018121-index.htm
2020-05-26Owen B. WallaceChief Scientific OfficerBuy412.007.843,230.08127,500.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014416/0000899243-20-014416-index.htm
2020-05-27Owen B. WallaceChief Scientific OfficerBuy448.007.843,512.32127,536.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014552/0000899243-20-014552-index.htm
2020-05-28Owen B. WallaceChief Scientific OfficerBuy2,232.007.8417,498.88129,320.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014719/0000899243-20-014719-index.htm
2020-07-08Owen B. WallaceChief Scientific OfficerBuy2,951.007.8423,135.84130,039.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320018817/0000899243-20-018817-index.htm
2020-02-19Owen B. WallaceChief Scientific OfficerBuy6,088.007.8447,729.92133,176.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320005299/0000899243-20-005299-index.htm
2020-09-14Owen B. WallaceChief Scientific OfficerBuy6,350.007.8449,784.00133,438.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320024982/0000899243-20-024982-index.htm
2020-05-11Peter G. ThomsonVP Finance & AccountingSell7,500.0016.00120,000.0021,071.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320012820/0000899243-20-012820-index.htm
2019-07-22Third Rock Ventures IV, L.P.10% Share HolderBuy81,250.0016.001,300,000.002,343,154.00https://www.sec.gov/Archives/edgar/data/1680581/000089924319020029/0000899243-19-020029-index.htm
2020-02-24Peter G. ThomsonVP Finance & AccountingSell250.0018.614,653.0028,571.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320005958/0000899243-20-005958-index.htm
2020-02-24Peter G. ThomsonVP Finance & AccountingSell2,102.0017.4336,643.3328,821.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320005958/0000899243-20-005958-index.htm
2020-02-24Peter G. ThomsonVP Finance & AccountingSell2,648.0016.1842,856.5630,923.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320005958/0000899243-20-005958-index.htm
2020-01-23Peter G. ThomsonVP Finance & AccountingSell262.0018.054,730.1233,571.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320002037/0000899243-20-002037-index.htm
2020-01-23Peter G. ThomsonVP Finance & AccountingSell4,738.0017.1781,371.8333,833.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320002037/0000899243-20-002037-index.htm
2020-07-08Robert J GouldOfficerSell2,500.0020.0050,000.00534,845.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320018815/0000899243-20-018815-index.htm
2020-06-25Robert J GouldOfficerSell2,500.0020.8051,992.00537,345.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320017758/0000899243-20-017758-index.htm
2020-06-09Robert J GouldOfficerSell156.0020.003,120.00539,845.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015959/0000899243-20-015959-index.htm
2020-06-05Robert J GouldOfficerSell3,433.0020.1769,251.16540,001.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015784/0000899243-20-015784-index.htm
2020-06-04Robert J GouldOfficerSell1,300.0020.0426,057.98543,434.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015437/0000899243-20-015437-index.htm
2020-06-03Robert J GouldOfficerSell1,500.0020.1330,192.45544,734.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015437/0000899243-20-015437-index.htm
2020-06-02Robert J GouldOfficerSell2,797.0020.0055,940.00546,234.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015063/0000899243-20-015063-index.htm
2020-06-01Robert J GouldOfficerSell5.0020.00100.00549,031.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015063/0000899243-20-015063-index.htm
2020-05-29Robert J GouldOfficerSell1,390.0020.0827,910.78549,036.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014721/0000899243-20-014721-index.htm
2020-05-28Robert J GouldOfficerSell1,919.0020.0138,391.13550,426.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014721/0000899243-20-014721-index.htm
2020-05-26Robert J GouldOfficerSell2,500.0020.0050,000.00552,345.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014415/0000899243-20-014415-index.htm
2020-02-19Robert J GouldOfficerSell2,500.0020.0050,000.00554,845.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320005300/0000899243-20-005300-index.htm
2019-07-22 Sanofi10% Share HolderBuy93,750.0016.001,500,000.00558,035.00https://www.sec.gov/Archives/edgar/data/1680581/000089924319020073/0000899243-19-020073-index.htm
2019-07-226 Dimensions Capital, L.P.10% Share HolderBuy118,750.0016.001,900,000.00559,821.00https://www.sec.gov/Archives/edgar/data/1680581/000110465919041307/0001104659-19-041307-index.htm
2019-07-22Casdin Capital, LLC10% Share HolderBuy125,000.0016.002,000,000.00589,285.00https://www.sec.gov/Archives/edgar/data/1680581/000110465919041306/0001104659-19-041306-index.htm
2019-07-22MARK J LEVINDirectorBuy81,250.0016.001,300,000.005,962,202.00https://www.sec.gov/Archives/edgar/data/1680581/000110465919041304/0001104659-19-041304-index.htm
2019-07-22Third Rock Ventures III, L.P.10% Share HolderBuy81,250.0016.001,300,000.005,962,202.00https://www.sec.gov/Archives/edgar/data/1680581/000089924319020026/0000899243-19-020026-index.htm
2019-07-22Casdin Capital, LLC10% Share HolderBuy10,000.0014.50144,996.00599,285.00https://www.sec.gov/Archives/edgar/data/1680581/000110465919041306/0001104659-19-041306-index.htm
2019-07-22Casdin Capital, LLC10% Share HolderBuy5,000.0014.5072,499.00604,285.00https://www.sec.gov/Archives/edgar/data/1680581/000110465919041306/0001104659-19-041306-index.htm
2020-07-01Diego CadavidSVP Clinical DevelopmentSell1,071.0018.3019,599.3065,714.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320018278/0000899243-20-018278-index.htm
2020-03-02Diego CadavidSVP Clinical DevelopmentSell315.0018.135,709.5366,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320006590/0000899243-20-006590-index.htm
2020-05-12Diego CadavidSVP Clinical DevelopmentSell1,860.0018.0033,480.0066,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320012822/0000899243-20-012822-index.htm
2020-05-28Diego CadavidSVP Clinical DevelopmentSell600.0020.0012,000.0066,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/0000899243-20-014722-index.htm
2020-05-29Diego CadavidSVP Clinical DevelopmentSell200.0020.044,007.0066,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/0000899243-20-014722-index.htm
2020-06-02Diego CadavidSVP Clinical DevelopmentSell45.0020.00900.0066,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/0000899243-20-015245-index.htm
2020-06-03Diego CadavidSVP Clinical DevelopmentSell338.0020.186,819.5966,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/0000899243-20-015245-index.htm
2020-06-04Diego CadavidSVP Clinical DevelopmentSell226.0020.054,531.2566,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/0000899243-20-015623-index.htm
2020-06-05Diego CadavidSVP Clinical DevelopmentSell451.0020.189,100.7766,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/0000899243-20-015623-index.htm
2020-06-10Diego CadavidSVP Clinical DevelopmentSell401.0022.008,822.0066,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320016382/0000899243-20-016382-index.htm
2020-06-25Diego CadavidSVP Clinical DevelopmentSell1,459.0022.0032,098.0066,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320017761/0000899243-20-017761-index.htm
2020-06-02Diego CadavidSVP Clinical DevelopmentBuy45.004.83217.3566,830.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/0000899243-20-015245-index.htm
2020-05-29Diego CadavidSVP Clinical DevelopmentBuy200.004.83966.0066,985.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/0000899243-20-014722-index.htm
2020-06-04Diego CadavidSVP Clinical DevelopmentBuy226.004.831,091.5867,011.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/0000899243-20-015623-index.htm
2020-03-02Diego CadavidSVP Clinical DevelopmentSell1,828.0017.2631,545.2567,100.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320006590/0000899243-20-006590-index.htm
2020-06-03Diego CadavidSVP Clinical DevelopmentBuy338.004.831,632.5467,123.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/0000899243-20-015245-index.htm
2020-06-10Diego CadavidSVP Clinical DevelopmentBuy401.004.831,936.8367,186.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320016382/0000899243-20-016382-index.htm
2020-06-05Diego CadavidSVP Clinical DevelopmentBuy451.004.832,178.3367,236.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/0000899243-20-015623-index.htm
2020-05-28Diego CadavidSVP Clinical DevelopmentBuy600.004.832,898.0067,385.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/0000899243-20-014722-index.htm
2020-06-25Diego CadavidSVP Clinical DevelopmentBuy1,459.004.837,046.9768,244.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320017761/0000899243-20-017761-index.htm
2020-05-12Diego CadavidSVP Clinical DevelopmentBuy1,860.004.838,983.8068,645.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320012822/0000899243-20-012822-index.htm
2020-02-03Diego CadavidSVP Clinical DevelopmentSell2,143.0017.3337,141.8368,928.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320003272/0000899243-20-003272-index.htm